摘要
Abstract
Objective To investigate the efficacy and safety of domestic recombinant human pro - urokinase in the treatment of acute myocardial infarction(AMI). Methods By computer - based retrieval,we searched for literature about the efficacy and safety of domestic recombinant human pro - urokinase in the treatment of AMI from PubMed,EMBase,Cochrane Library,CBM,CNKI,CQVIP and Wanfang Data with a time range from database establishment to September 2015. Two researchers independently conducted literature screening and quality evaluation,extracted data including the first author, publishing time,treatment time,age,volume of samples,dosage and evaluation indexes by a table designed in advance. Heterogeneity analysis was firstly conducted after literature inclusion,and odds ratio(OR)and its 95% CI were used as effect size. Results A total of 10 pieces of literature were included,concerning 875 AMI patients,and were at grade B in terms of literature methodology quality. Domestic recombinant human pro - urokinase was higher in recanalization rate〔 OR = 2. 63, 95% CI(1. 95,3. 54)〕and complete recanalization rate〔 OR = 2. 85,95% CI(2. 09,3. 89)〕and was lower in 30 - day MACE incidence〔OR = 0. 42,95% CI(0. 27,0. 65)〕,slight bleeding incidence〔OR = 0. 52,95% CI(0. 33,0. 81)〕and bleeding incidence〔OR = 0. 41,95% CI(0. 28,0. 62)〕than urokinase in the treatment of AMI(P < 0. 05). There was no significant difference between domestic recombinant human pro - urokinase and urokinase for AMI patients in the severe bleeding incidence〔OR = 0. 24,95% CI(0. 05,1. 12),P = 0. 07〕. Conclusion Compared with urokinase,domestic recombinant human pro - urokinase leads to high recanalization rate,low MACE incidence and less bleeding complications in the treatment of AMI patients.关键词
心肌梗死/尿激酶型纤溶酶原激活物/主要不良心血管事件/出血/Meta 分析Key words
Myocardial infarction/Urokinase - type plasminogen activator/Major adverse cardiac events/Hemorrhage/Meta - analysis分类
医药卫生
